Sobre 2 señales de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Browse the full record of transactions filed by Redmile Group, LLC. Officer active across 17 companies, notably Fate Therapeutics INC. Cumulatively, 81 reports have been logged. Split: 18 buys · 9 sells. Total volume traded: €43m. Activity tracked since 2 June 2021. The latest transaction was filed on 6 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Redmile Group, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
400.000 títulos@ 2,81 US$86.9% de su flujoCommon Shares, par value CHF 0.08 per shareSEC:0001104659-24-077865:0
Salida canónica: 29 sept 2024 (T+90)
25 de 81 declaraciones
About Redmile Group, LLC
Redmile Group, LLC has 76 filings in total. In the sampled recent filings we hold, from 2016-01-11 to 2026-04-22, the reported buy amount is EUR 16224333 and the reported sell amount is EUR 52839723. The modal transaction nature is Attribution; the listed companies include IGM Biosciences, Inc., Augmedix, Inc., Fate Therapeutics INC, ADC Therapeutics SA, ARRAY BIOPHARMA INC, and Science 37 Holdings, Inc.